AstraZeneca’s investment U-turn shows the UK is “a global destination for life sciences investment”, the ABPI’s Chief Executive has said. Richard Torbett was speaking after AstraZeneca announced it would resume large-scale activity in the UK with a £300 million ($405 million) investment. The drugmaker had previously rolled back on investment in the UK but is now […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!